Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 15;15:17534666211028072. doi: 10.1177/17534666211028072

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Clinical values of serum CASC2 in COPD patients. (a) Serum CASC2 was low expressed in the smokers compared with non-smokers, and it was dramatically decreased in COPD patients compared with smokers without COPD. **p < 0.01; ^###p < 0.001. Differences between groups were compared using one-way analysis of variance. (b) Serum CASC2 was positively associated with FEV1 in all smokers with or without COPD (r = 0.731, p < 0.001). Differences between groups were compared using Student’s t-test. (c) CASC2 was downregulated significantly in the serum of COPD patients in stage I-II compared with that in stage III. ***p < 0.001, compared with stage I–II group. (d) CASC2 had the diagnostic accuracy to distinguish COPD patients from smokers with the AUC of 0.924, the sensitivity of 78.0% and the specificity of 92.0%.

AUC, area under the curve; CASC2, cancer susceptibility candidate 2; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second.